Peter Thornton is senior vice president of corporate development for Northwell Holdings and Ventures, the health system’s for-profit subsidiary which is tasked with generating recurring revenues to support the health system. His responsibilities cover corporate development and venture investing activities.
A senior financial and operational executive with over 20 years of experience, Mr. Thornton’s expertise covers capital markets, corporate and business development and operations, including raising more than $100 million, multiple mergers, acquisitions and sales, acquisition integrations, technology and product license agreements and successful growth and innovation strategies.
He joined Northwell in 2019 after serving as executive vice president and chief financial officer of Technopath Clinical Diagnostics, an Irish-based business focused on developing and manufacturing total quality control solutions for clinical laboratories. In this role, Mr. Thornton was a key part of the management team which grew the business five-fold over a five-year period. During this period Technopath successfully entered the US health care market, secured long term growth funding and divested non-core businesses including two successful life science technology spin-outs.
Prior to Technopath, Mr. Thornton held several senior leadership positions for biotech and pharma organizations, including senior vice president of business integration for Alkermes plc, senior vice president of corporate and business development for Elan Drug Technologies and chief financial officer of Agenus Inc. Mr. Thornton still serves as a non-executive director of NASDAQ-listed Avadel Pharmaceuticals plc, leon-nanodrugs GmbH, Oculer Limited and Waverley Pharma Europe Limited.
Mr. Thornton is a fellow of Chartered Accountants Ireland, having worked with KPMG in Ireland and France. He holds a Bachelor of Commerce degree from University College Cork, Ireland.